ElevateBio

ElevateBio is a technology-driven company built to power the development of transformative cell and gene therapies today and for many decades to come.

ElevateBio's mission is to power the creation of life-transforming cell and gene therapies, at a speed the world deserves.

ElevateBio was founded in 2017 by David Hallal, Mitchell H. Finer, and Vikas Sinha. The company is headquartered in Cambridge, Massachusetts, with ElevateBio BaseCamp located in Waltham, Massachusetts.

 

The ElevateBio ecosystem combines multiple R&D technology platforms – including Life Edit, a next-generation, full-spectrum gene-editing platform; a proprietary induced pluripotent stem cell (iPSC) platform, and an RNA, cell, protein, and vector engineering platform – with BaseCamp®, its end-to-end genetic medicine cGMP manufacturing and process development business, to power the discovery and development of advanced therapeutics.

 

ElevateBio is also building a highly innovative pipeline of cellular, genetic, and regenerative medicines. ElevateBio has supercharged its gene editing capabilities through the acquisition, integration, and growth of Life Edit’s novel RGN and base editing technologies, leading to multiple partnerships, including the recently announced collaborations with Moderna and Novo Nordisk.

 

ElevateBio has also expanded access to its iPSC platform technology through a partnership with the California Institute for Regenerative Medicine and the formation of a new company aimed at developing iPSC-derived allogeneic immune cell therapies. 

 

ElevateBio is backed by Fidelity Management & Research Company, Novo Nordisk, SoftBank Vision Fund 2, MPM Capital, Matrix Capital Management, EcoR1 Capital, Redmile Group, F2 Ventures, Vertex Ventures, Samsara BioCapital, The Invus Group, Woodline, Emerson Collective, Surveyor Capital, EDBI, iTochu, and others. The company raised $401M in a Series D round on May 24, 2023. This brings ElevateBio's total funding to $1.25B to date.

 

 

  • Year founded: 2017
  • Funding Info: $1.25B over 4 Rounds (Latest Funding Type: Series D)
  • Yearly Revenue: NA
  • Employee Size: 201-500
  • Business Valuation: NA
  • City/Town: Waltham
  • State: Massachusetts
  • Country: United States
Related businesses